One contribution of 13 to a theme issue 'The biomedical applications of graphene'. Reliable data obtained from analysis of DNA, proteins, bacteria and other disease-related molecules or organisms in biological samples have become a fundamental and crucial part of human health diagnostics and therapy. The development of non-invasive tests that are rapid, sensitive, specific and simple would allow patient discomfort to be prevented, delays in diagnosis to be avoided and the status of a disease to be followed up. Bioanalysis is thus a progressive discipline for which the future holds many exciting opportunities. The use of biosensors for the early diagnosis of diseases has become widely accepted as a point-of-care diagnosis with appropriate specificity in a short time. To allow a reliable diagnosis of a disease at an early stage, highly sensitive biosensors are required as the corresponding biomarkers are generally expressed at very low concentrations. In the past 50 years, various biosensors have been researched and developed encompassing a wide range of applications. This contrasts the limited number of commercially available biosensors. When it comes to sensing of biomarkers with the required picomolar ( pM) sensitivity for real-time sensing of biological samples, only a handful of sensing systems have been proposed, and these are often rather complex and costly. Lately, graphene-based materials have been considered as superior over other nanomaterials for the development of sensitive biosensors. The advantages of graphene-based sensor interfaces are numerous, including enhanced surface loading of the desired ligand due to the high surface-to-volume ratio, excellent conductivity and a small band gap that is beneficial for sensitive electrical and electrochemical read-outs, as well as tunable optical properties for optical read-outs such as fluorescence and plasmonics. In this paper, we review the advances made in recent years on graphene-based biosensors in the field of medical diagnosis.
Introduction
Biosensors are analytical devices that convert a biochemical/biological reaction into a measurable physico-chemical signal, which is proportional to the analyte concentration. A typical biosensor thus consists of two elements: a surfacelinked biological component that interacts selectively with the analyte of interest in blood or serum and a transducer for the detection of the analytebinding event on the surface. The major advantage of using biosensors compared with other conventional biochemical assays such as immunoassays and polymerase chain reaction based strategies is the fast response time (normally several minutes) along with high specificity. The first biosensor reported dates back to the work by Leland C. Clark, who is considered to be the father of biosensors. Based on his experience with the oxygen electrode [1] , he proposed making electrochemical sensors more intelligent by entrapping enzymes such as glucose oxidase onto the oxygen electrode using a dialysis membrane [2] . This glucose analyser became commercially available in 1975 in the form of an amperometric sensor. The idea of immobilizing antibodies rather than enzymes on the sensor transducer emerged in the early 1980s with the work by Lieberg et al. [3] . This work paved the way for the commercial success of surface plasmon resonance (SPR) biosensors (Biacore Technology, launched in 1990); these devices rely on monitoring the change in the plasmonic signal upon antibody-antigen affinity reaction in real time. Since then various biosensors have been developed encompassing a wide range of applications.
One of the many remaining challenges in biosensor development concerns the efficient and selective capture of the biological recognition event. In order to achieve the often requested picomolar ( pM) limit of detection (LOD) for biological analytes, nanomaterials have been intensively investigated as candidates for transducer coatings. The possibility of enhancing the amount of bioreceptor immobilization with consequently improved signal read-out makes this biosensor approach greatly appealing. Among the different nanomaterials considered [4] , graphene and its various forms such as graphene oxide (GO), reduced graphene oxide (rGO), graphene nanoribbons (GNRs) and so on have received worldwide attention for the development of biosensors. Different sensing mechanisms including optical, electrochemical or electrical can be employed with graphene-based biosensors, in the following noted as G-biosensors. In the case of electrochemical (amperometric, voltammetric, impedimetric) G-biosensors and electrical sensing concepts (graphene-based field effect transistors (G-FETs)), the high electron transfer rates, high charge-carrier mobility and low electrical noise levels are of utmost importance for highly sensitive detection of biomarkers and other biological analytes in serum and blood samples [5, 6] . Furthermore, chemically derived graphene derivatives exhibit a high density of edge-plane-like defect sites, providing many active sites for electron transfer to chemical and biological species [5] . Also, the high optical transparency of graphene monolayers makes them ideal materials for optical-based G-biosensors and highly beneficial to improve the sensing performance of plasmonic sensors [7] . The fluorescence quenching ability of GO resulted in the development of several fluorescence resonance energy transfer (FRET)-based G-biosensors [8] . Graphene has also been shown to be an emerging material as a surfaceenhanced Raman substrate (SERS) due to its ability to generate strong chemical enhancement [9] . Independent of the detection method adopted, the presence of hydrophobic domains or psystems on graphene-based transducers renders them excellent supporting layers for immobilization of biomolecules. However, the control of non-specific interactions becomes even more important when compared with other sensing surfaces, especially when analysing biological liquids [10] . Improvement in the fabrication of non-fouling graphene transducers is one of the essential steps in the development of high-performance G-biosensors [10] .
To obtain a general overview of the results achieved in this field, some of the key works around the development of pointof-care sensing in biological fluids using G-biosensors will be highlighted here. As the examples of G-biosensors are countless, the focus will be on the direct detection of small molecules such as glucose and dopamine, DNA and protein biomarkers (e.g. folic acid protein, lysozyme, prostate-specific antigen) using immunosensing, and also on pathogen detection. It is hoped that this brief overview of G-biosensors and their interest for the biomedical field will stimulate further research activities together with commercialization of some of the proposed concepts to help advance personalized care.
Preparation of graphene-based biosensors
A number of different approaches for the synthesis of graphene and its derivatives such as GO, rGO, porous-reduced graphene oxide (prGO) and GNRs are available in the literature (figure 1). Large area single and few layer high-quality graphene nanosheets can be produced by chemical vapour deposition (CVD) methods on nickel or copper and are commercially accessible. Such graphene sheets are nowadays routinely transferred to any transducer interface using mainly polydimethylsiloxane supported transfer processes [11] . The high quality of CVD graphene and the possibility of obtaining mono-and bilayer modified electrical interfaces makes such electrodes advantageous for G-FETs and plasmonic biosensing. The use of chemically derived GO and rGO nanosheets, obtained from a graphite precursor through solution-based exfoliation aiming at weakening the van der Waals forces between the graphene layers, is the most commonly used synthetic approach for the construction of G-biosensors. It is a relatively cheap method for obtaining GO/rGO on a large scale, with the additional benefit of possible modulation of the morphology and porosity of the nanosheets. Furthermore, doping with non-metallic elements such as nitrogen, sulfur or boron allows the electronic structure of these materials to be modulated and leads, in general, to improved electrical and electro-catalytic properties.
Reduction of the GO-flake size results in better dispersible structures of 3-20 nm in size consisting of no more than five layers; these structures exhibit a high surface area and are termed graphene quantum dots (GQDs) [12] . Different techniques such as drop-casting, spin-coating, electrostatic interaction between positively charged interfaces and the negatively charged GO/rGO nanosheets, electrophoretic deposition (EPD) and electrochemical reduction of GO can be employed to coat electrical as well as inert surfaces with the chemically derived graphene materials. The method of choice depends on the use after application and the employed transducer element. Table 1 gives a short list of selected biological analytes of interest together with the method employed for their detection and the LOD which can be reached, most of them being discussed in more detail in this review.
G-biosensors for glucose and dopamine
One challenging and important molecule to monitor is glucose. An increase in glucose levels is critical for human health as hyperglycaemia, defining diabetes, leads to premature death caused by macrovascular and microvascular complications. Close monitoring of the blood glucose concentration can largely help to manage diabetes. Tremendous efforts have been put into the development of efficient and reliable methods for glucose sensing. Graphene-based glucose sensors are generally built by immobilizing glucose oxidase (GO x ) onto the graphene surface, such as the graphene-FET proposed by Huang et al. [24] (figure 2a). In this work, GO x was covalently linked via its amine groups to 1-pyrenebutanoic acid succinimidyl ester, where the pyrene end is firmly attached to graphene through p-p stacking interactions. Measuring a change in conductance allowed glucose detection down to 0.1 mM. Although the use of GO x allows for high selective detection of glucose, non-enzymatic glucose sensors based on the integration of electro-catalytic sites for glucose, often in the form of nanoparticles (NPs), onto graphene have been pursued [13, 25, 26] . While these sensors are less selective to glucose and need to be for the most part operated in an alkaline medium, they display several advantages such as better stability than GO x -based interfaces and often improved sensitivity with detection limits in the low micromolar to nanomolar range. In the case of N-doped prGO loaded with Cu NPs (N-prGO-Cu NPs) the improved sensitivity to glucose is attributed to the electro-catalytic behaviour of the CuO/CuOOH couple (figure 2b). In the presence of glucose, the redox peak of Cu(0)/Cu(I) stays unchanged, while the peak of the Cu(I)/Cu(II) transition is decreased, reflecting the formation of a Cu(I)-glucose complex. The band at þ0.4 V is strongly increased, in line with the activity of Cu(III) in basic medium (figure 2b) [27] .
A different non-enzymatic glucose-sensing approach based on the use of GQDs modified with boronic acid-substituted bipyridine ligands, which serve as a fluorescence quencher upon electrostatic interaction with GQDs, was proposed [14] (figure 2c). When glucose is added to the system, the boronic acid moieties are converted to tetrahedral anion glucoboronate esters, which neutralize the net charge of the bipyridinium, thus greatly diminishing the quenching effect and recovering the fluoresence intensity of the GQDs (figure 2c).
Another small biomolecule of interest is dopamine. It is one of the crucial catecholamine neurotransmitters widely found in serum samples at concentrations between 10 nM and 1 mM. Abnormal levels can result in a variety of diseases Table 1 . Selected examples of most performing graphene-based biosensors for different analytes. 3D, three-dimensional; EC, electrochemistry; FET, field effect transistor; FRET, fluorescence resonance energy transfer; GO, graphene oxide; rGO, reduced graphene oxide; GQDs, graphene quantum dots; GO x , glucose oxidase; Au NPs, gold nanoparticles; DPV, differential pulse voltammetry; LOD, limit of detection; PDDA, poly(diallyldimethylamonium); PSA, prostate-specific antigen; SERS, surface-enhanced Raman substrate; SPR, surface plasmon resonance; ssDNA, single-stranded DNA. 
DNA sensing with G-biosensors
The need for rapid and sensitive DNA analysis is an important issue in clinical diagnosis. Major studies have focused on the sequence-specific recognition of ssDNA and on the detection of single nucleotide polymorphisms (SNPs). SNPs are a common form of genomic variation occurring in every 100-300 bp and are related to many major diseases and disorders, such as Parkinson's disease, Alzheimer's disease, diabetes and various cancers. The development of analytical approaches for selective DNA sensing has consequently been strongly pursued with the belief that low-cost systems suitable for DNA analysis could revolutionize modern healthcare. Electrodes modified with graphene oxide nanowalls (GONs) with preferred vertical orientation [17] or graphene nanoplatelets [30] are capable of catalytically oxidizing the four DNA bases simultaneously, resulting in DNA sensors with an LOD as low as 9.4 zM [17] (figure 3a). The fluorescence quenching ability of GO was exploited by several research groups for the detection of hybridization events. When a dye-labelled ssDNA is immobilized via noncovalent binding onto GO, the fluorescence is quenched; this non-covalent interaction is reversible. ssDNA interaction with GO occurs thus via p 2 p stacking, hydrophobic interactions and hydrogen bonding. Even though both GO and ssDNA are negatively charged, DNA can be adsorbed on GO in buffers containing a high concentration of salts to screen electrostatic repulsion [31] . In double-stranded DNA (dsDNA), the nucleotide bases are hidden in the helical structures, preventing their effective interaction with the GO surface in contrast to ssDNA. In the presence of a complementary DNA (cDNA) target, a duplex is formed, disturbing the GO-ssDNA interaction and resulting in the release of the formed dsDNA, at which point fluorescence is restored ( figure 3b ). This approach has been recently used in combination with ssDNA-modified GQDs for FRET-based DNA sensing [16] (figure 3b).
This concept was further applied to SPR-based DNA sensing [11] (figure 3c). Gold nanostars modified with ssDNA were integrated into commercially available graphene-coated SPR chips. As dsDNA has a lower affinity to graphene, hybridized targets are released from the graphene surface, resulting in a negative shift of the SPR signal; this allows easy discrimination between mismatched DNA and offers a label-free approach for DNA detection with an LOD of 500 aM over a linear dynamic range up to 10 nM [11] .
The feasibility of G-FET-based sensors for nucleic acidbased analytes has been shown by Zheng et al. [18] . Peptide nucleic acid (PNA) was non-covalently immobilized to the graphene channel and hybridization with target DNA produced a left-shift in the Dirac point with an LOD of 10 fM [18] . Dontschuk et al. [32] have also shown the usefulness of G-FETs for DNA sequencing. They demonstrated experimentally that G-FETs are able to measure distinct coveragedependent conductance signatures upon adsorption of the four different DNA nucleobases-a result that was attributed to the formation of an interface dipole field.
G-based sensors for protein biomarkers
Protein biomarkers are specific molecules existing in blood or tissues, whose measurement or identification is very critical and efficient in the prediction, diagnosis and monitoring of cancer and many other diseases. The clinical utility of biomarkers to diagnose disease requires the capability to measure femto-to picomolar concentrations of these, which is also important to understand cellular processes and to search for new protein biomarkers. The LODs of the prevailing analytical protocols (e.g. enzyme-linked immunosorbent assays) for biomarker detection lag far behind the requirements for clinical utility and research. Graphenebased immunoassay platforms, where specific antibodies are immobilized onto graphene to capture selectively the biomarker analyte, have shown on the other hand excellent sensitivity [33] (figure 4). For example, we have recently demonstrated that post-functionalization of rGO-modified electrodes by simple immersion into a solution of folic acid allowed for the development of an electrochemical-based sensor for folic acid protein with an LOD of 1 pM [10] (figure 4a) and a plasmonic sensor with a 5 fM LOD [20] . Levels of folic acid protein in serum can increase up to 22 pM in metastic diseases. Given that human serum is free of folic acid proteins, detection of this protein in serum serves as an early stage cancer diagnostic step.
A rGO-based FET modified with prostate-specific antigena 1 -antichymotrypsin (PSA-ACT) was used by Kim et al. [22] to detect fM levels of PSA with a dynamic range over six orders of magnitude ( figure 4b ). An SPR-based read-out was used by Cosnier and co-workers [34] for the detection of cholera toxin on graphene-coated gold chips modified with pyrenenitrilotriacetic acid (NTA) with an LOD of 5 pg ml 21 . We showed recently the suitability of Micrococcus lysodeikticusmodified GO-coated SPR interfaces to sense serum lysozyme levels with an LOD of 3.4 nM [19] (figure 4c). Lysozyme, an enzyme found in biological fluids, is upregulated in leukaemia, renal diseases as well as a number of inflammatory diseases. While lysozyme concentration in the serum of healthy people ranges from 27 to 301 nM, patients with inflammatory bowel One main hurdle of all these sensors when performing tests in human serum samples, often not evoked in the literature, is linked to the high non-specific interaction between the graphene surface and serum proteins. We have compared a number of different strategies to reduce non-specific binding of clinical serum samples spiked with lysozyme (100 mM) on rGO [20] (figure 4e). While simple immersion into serum decreased strongly the anti-fouling properties of graphene, rGO modification with pyrene-polyethylene glycol (PEG) units has been shown to result in the best non-fouling interface [20, 35] .
Bacteria and viruses
The specific and sensitive detection of pathogenic microorganisms remains a big scientific challenge and a practical problem of enormous significance. Pathogen diagnosis is currently based on culturing the microorganism on agar plates with the disadvantage of being long (minimum of 24 h) and ignoring viable but non-culturable cells. G-FET biosensors have been successfully applied for the detection of bacteria and their metabolic activities. CVD graphene modified with anti-Escherichia coli antibodies allowed E. coli concentrations as low as 10 cfu ml 21 to be detected [23] . Graphene oxide in combination with E. coli O157:H7 antibody-conjugated quantum dots was used as a pathogen-revealing agent by exploiting the universal highly efficient long-range quenching properties of GO; an LOD of 3.8 Â 10 3 cfu ml 21 was achieved [36] . Graphene printed onto water-soluble silk and modified with antimicrobial peptides allowed bioselective detection of bacteria at single-cell levels remotely [37] .
Conclusion and perspectives
We tried to review the most recent advances in graphene-based biosensors by selectively highlighting a variety of different examples for the detection of some molecules of biomedical interest. Routinely, such sensors achieve a picomolar LOD, with some even reaching the low femtomolar concentration range. The possibility that a large range of different detection methods can be employed with graphene-based sensors is of high advantage, as depending on the looked after final application, sensor size and read-out can be customized at will. There is, however, still an urgent need for moving beyond research by developing new concepts for achieving even better sensitivity and selectivity, in order to bring some of the current sensors into real biomedical applications. Even though a large number of sensors reported in the literature exhibit good storage stability and repeatability which are important for complex sensors involving nanomaterials and manual step preparations, the performance in real biological 
PSA mAb 100 fg ml-1 1 pg ml-1 10 pg ml-1 10 ng ml-1 100 ng ml-1 1 ug ml-1 100 pg ml-1 1 ng ml-1 pH 7.4 samples is often not reported. As non-specific interactions are of primary concern in graphene-based interfaces, this lack of information together with the large-scale reproducibility of the fabrication of graphene biosensor interfaces are probably two of the most crucial limiting factors for current commercialization. When it comes to in vivo application of some of the sensing concepts, graphene-based biosensors are still in their infancy. Toxicity and biocompatibility issues still need to be addressed carefully to avoid any undesired secondary health effects. Current in vivo and in vitro assessments of the biostability of the sensors are encouraging and promising for further technological transfer. Different challenges are still to be overcome. The collaboration between material scientists, chemists, physicists as well as engineers and medical personnel is of fundamental importance to drive this field further and to propose graphene-based biosensors as point-of-care alternatives for patients. The success of any new biosensor material lies in addition in its reproducibility and possible industrial-scale production. The emergence of a number of companies providing mono-and bilayered graphene nanosheets on several interfaces, GO, rGO and even modified matrices, has been an additional motivation for using graphene for biosensor applications.
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